

Stephen G Ellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/593386/publications.pdf>

Version: 2024-02-01

166
papers

21,418
citations

22153

59
h-index

8866

145
g-index

168
all docs

168
docs citations

168
times ranked

14267
citing authors

#	ARTICLE	IF	CITATIONS
1	A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2004, 350, 221-231.	27.0	2,601
2	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	2.8	2,027
3	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
4	Safety and Efficacy of Sirolimus- and Paclitaxel-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2007, 356, 998-1008.	27.0	1,776
5	Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. <i>Lancet, The</i> , 2003, 362, 697-703.	13.7	1,199
6	Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries. <i>Circulation</i> , 1996, 94, 1690-1697.	1.6	726
7	Localized Intracoronary Gamma-Radiation Therapy to Inhibit the Recurrence of Restenosis after Stenting. <i>New England Journal of Medicine</i> , 2001, 344, 250-256.	27.0	608
8	Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2205-2217.	27.0	596
9	Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2015, 373, 1905-1915.	27.0	554
10	Relationship Between Delay in Performing Direct Coronary Angioplasty and Early Clinical Outcome in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 1999, 100, 14-20.	1.6	532
11	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Circulation</i> , 2011, 124, 2574-2609.	1.6	500
12	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2110.	7.4	377
13	Bare metal stent restenosis is not a benign clinical entity. <i>American Heart Journal</i> , 2006, 151, 1260-1264.	2.7	367
14	Significance of Mild Transient Release of Creatine Kinaseâ€œMB Fraction After Percutaneous Coronary Interventions. <i>Circulation</i> , 1996, 94, 1528-1536.	1.6	305
15	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. <i>Lancet, The</i> , 2016, 387, 1277-1289.	13.7	253
16	Paclitaxel-Eluting Stents vs Vascular Brachytherapy for In-Stent Restenosis Within Bare-Metal Stents. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1253.	7.4	243
17	Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention. <i>Circulation</i> , 2001, 104, 992-997.	1.6	241
18	Long-Term Clinical Outcomes After Unprotected Left Main Trunk Percutaneous Revascularization in 279 Patients. <i>Circulation</i> , 2001, 104, 1609-1614.	1.6	217

#	ARTICLE	IF	CITATIONS
19	Death Following Creatine Kinase-MB Elevation After Coronary Intervention. <i>Circulation</i> , 2002, 106, 1205-1210.	1.6	204
20	Emergency Coronary Artery Bypass Surgery in the Contemporary Percutaneous Coronary Intervention Era. <i>Circulation</i> , 2002, 106, 2346-2350.	1.6	195
21	Contemporary Percutaneous Treatment of Unprotected Left Main Coronary Stenoses. <i>Circulation</i> , 1997, 96, 3867-3872.	1.6	182
22	Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation. <i>Circulation</i> , 2007, 115, 2842-2847.	1.6	162
23	Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experience. <i>Journal of the American College of Cardiology</i> , 1995, 26, 704-712.	2.8	161
24	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 453-495.	1.7	157
25	Angiographic Surrogate End Points in Drug-Eluting Stent Trials. <i>Journal of the American College of Cardiology</i> , 2008, 51, 23-32.	2.8	153
26	Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 541-545.	1.7	151
27	Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1193-1200.	2.8	149
28	Insights Into Timing, Risk Factors, and Outcomes of Stroke and Transient Ischemic Attack After Transcatheter Aortic Valve Replacement in the PARTNER Trial (Placement of Aortic Transcatheter) <i>Tj ETQq0 0 0 rgB3,0 Overlock45 Tf 50 3</i>	2.8	145
29	A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2030-2036.	2.4	143
30	Identification of Four Gene Variants Associated with Myocardial Infarction. <i>American Journal of Human Genetics</i> , 2005, 77, 596-605.	6.2	142
31	Impact of Routine Angiographic Follow-Up on the Clinical Benefits of Paclitaxel-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 48, 32-36.	2.8	134
32	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2018, 39, 1726-1735a.	2.2	133
33	Low-Normal or Excessive Body Mass Index: Newly Identified and Powerful Risk Factors for Death and Other Complications With Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 1996, 78, 642-646.	1.6	130
34	Influence of Transcatheter Aortic Valve Replacement Strategy and Valve Design on Stroke After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2101-2110.	2.8	123
35	Impact of mitral regurgitation on long-term survival after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2002, 89, 315-318.	1.6	122
36	Long-Term Safety and Efficacy With Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1248-1259.	2.9	122

#	ARTICLE	IF	CITATIONS
37	Incidence, Timing, and Correlates of Stent Thrombosis With the Polymeric Paclitaxel Drug-Eluting Stent. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1043-1051.	2.8	121
38	Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 93, 679-684.	1.6	117
39	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2550-2583.	2.8	114
40	Paclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2008, 51, 708-715.	2.8	106
41	Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. <i>Lancet, The</i> , 2018, 392, 1530-1540.	13.7	103
42	Left Main Coronary Artery Stenosis. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1219-1230.	2.9	101
43	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E266-355.	1.7	97
44	4-Step Protocol for Disparities in STEMI Care and Outcomes in Women. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2122-2132.	2.8	97
45	Comparison of Percutaneous Versus Surgical Revascularization of Severe Unprotected Left Main Coronary Stenosis in Matched Patients. <i>American Journal of Cardiology</i> , 2008, 101, 169-172.	1.6	96
46	Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade. <i>American Journal of Cardiology</i> , 2000, 86, 780-782.	1.6	93
47	Relation Between Lesion Characteristics and Risk With Percutaneous Intervention in the Stent and Glycoprotein IIb/IIIa Era. <i>Circulation</i> , 1999, 100, 1971-1976.	1.6	88
48	Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. <i>American Heart Journal</i> , 2004, 147, 684.	2.7	88
49	Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation. <i>Journal of the American College of Cardiology</i> , 2005, 45, 1201-1205.	2.8	88
50	Characterization of Post-Operative Risk Associated With Prior Drug-Eluting Stent Use. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 542-549.	2.9	76
51	Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 917-924.	2.9	76
52	Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions. <i>Circulation</i> , 2000, 102, 28-34.	1.6	69
53	Analysis and Comparison of Operator-Specific Outcomes in Interventional Cardiology. <i>Circulation</i> , 1996, 93, 431-439.	1.6	66
54	Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction. <i>Circulation Research</i> , 2014, 115, 867-874.	4.5	65

#	ARTICLE	IF	CITATIONS
55	Granulocyte colony stimulating factor in patients with large acute myocardial infarction: Results of a pilot dose-escalation randomized trial. <i>American Heart Journal</i> , 2006, 152, 1051.e9-1051.e14.	2.7	63
56	Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, e002453.	3.9	61
57	Long-term Outcome of Transient, Uncomplicated In-Laboratory Coronary Artery Closure. <i>Circulation</i> , 1995, 91, 2733-2741.	1.6	60
58	1-Year Survival in a Randomized Trial of Facilitated Reperfusion. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 909-916.	2.9	59
59	Measures to Reduce Radiation in a Modern Cardiac Catheterization Laboratory. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 447-455.	3.9	59
60	Is traditionally defined complete revascularization needed for patients with multivessel disease treated by elective coronary angioplasty?. <i>Journal of the American College of Cardiology</i> , 1993, 22, 1289-1297.	2.8	58
61	Long-Term Safety and Efficacy of Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 530-542.	2.9	57
62	Reduction in Myocardial Infarct Size by Basic Fibroblast Growth Factor After Temporary Coronary Occlusion in a Canine Model. <i>Circulation</i> , 1996, 94, 1927-1933.	1.6	57
63	Cause of Death Within 30 Days of Percutaneous Coronary Intervention in an Era of Mandatory Outcome Reporting. <i>Journal of the American College of Cardiology</i> , 2013, 62, 409-415.	2.8	56
64	The State of the Absorb Bioresorbable Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2349-2359.	2.9	55
65	Two-year clinical outcomes after paclitaxel-eluting stent or brachytherapy treatment for bare metal stent restenosis: the TAXUS V ISR trial. <i>European Heart Journal</i> , 2008, 29, 1625-1634.	2.2	54
66	Long-Term Mortality in Patients With Radiation-Associated Coronary Artery Disease Treated With Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	46
67	Predictors of Successful Hybrid-Approach Chronic Total Coronary Artery Occlusion Stenting. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1089-1098.	2.9	43
68	Percutaneous Intervention for Myocardial Infarction After Noncardiac Surgery. <i>Journal of the American College of Cardiology</i> , 2016, 68, 329-338.	2.8	42
69	Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1041-1048.	2.8	41
70	Impact of lean six sigma process improvement methodology on cardiac catheterization laboratory efficiency. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 95-101.	0.8	40
71	Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 203-212.	2.9	37
72	β-Blockers Before Percutaneous Coronary Intervention Do Not Attenuate Postprocedural Creatine Kinase Isoenzyme Rise. <i>Circulation</i> , 2001, 104, 2685-2688.	1.6	36

#	ARTICLE	IF	CITATIONS
73	Evidence that angiotensin-converting enzyme inhibitor use diminishes the need for coronary revascularization after stenting. <i>American Journal of Cardiology</i> , 2002, 89, 937-940.	1.6	35
74	Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2363-2371.	2.9	35
75	Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2002, 40, 669-675.	2.8	34
76	Real-world bare metal stenting: Identification of patients at low or very low risk of 9-month coronary revascularization. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 63, 135-140.	1.7	33
77	Associations Between Cardiac Troponin, Mechanism of Myocardial Injury, and Long-Term Mortality After Noncardiac Vascular Surgery. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	33
78	Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: Initial U.S. feasibility trial using the Duett vascular closure device. <i>Catheterization and Cardiovascular Interventions</i> , 2000, 50, 96-102.	1.7	32
79	Safety of Bridging With Eptifibatid for Patients With Coronary Stents Before Cardiac and Non-Cardiac Surgery. <i>American Journal of Cardiology</i> , 2012, 110, 485-490.	1.6	32
80	High-Risk Coronary Atheroma. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1134-1140.	2.8	32
81	Utility of Glycated Hemoglobin for Assessment of Glucose Metabolism in Patients With ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 117, 749-753.	1.6	30
82	Evaluation of Infarct-Related Coronary Artery Patency and Microcirculatory Function After Facilitated Percutaneous Primary Coronary Angioplasty. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1284-1291.	2.9	29
83	Prognostic Value of Estimated Functional Capacity Incremental to Cardiac Biomarkers in Stable Cardiac Patients. <i>Journal of the American Heart Association</i> , 2014, 3, e000960.	3.7	29
84	Recognized Obstructive Sleep Apnea is Associated With Improved In-Hospital Outcomes After ST Elevation Myocardial Infarction. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	29
85	Excimer Laser Atherectomy in Percutaneous Coronary Intervention: A Contemporary Review. <i>Cardiovascular Revascularization Medicine</i> , 2021, 25, 75-85.	0.8	29
86	Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency. <i>American Journal of Cardiology</i> , 2002, 89, 1209-1211.	1.6	28
87	Management of drug eluting stent restenosis: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1080-1091.	1.7	28
88	Association of Glycemic Control With Mortality in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 503-509.	3.9	26
89	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1809-1815.	2.9	26
90	Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenoses: results of a multicenter 350-patient case-control study. <i>Journal of Invasive Cardiology</i> , 2007, 19, 404-9.	0.4	26

#	ARTICLE	IF	CITATIONS
91	Drug-eluting versus bare-metal stents for treating saphenous vein grafts. <i>American Heart Journal</i> , 2009, 158, 637-643.	2.7	25
92	Prognostic Significance of Ischemic Mitral Regurgitation on Outcomes in Acute ST-Elevation Myocardial Infarction Managed by Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 119, 20-26.	1.6	25
93	Comparison of three coronary stents: Clinical and angiographic outcome after elective placement in 134 consecutive patients. <i>Catheterization and Cardiovascular Diagnosis</i> , 1994, 33, 199-204.	0.3	21
94	Enhanced Prediction of Mortality After Percutaneous Coronary Intervention by Consideration of General and Neurological Indicators. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 442-448.	2.9	21
95	Clinical, Angiographic, and Procedural Correlates of Very Late Absorbable Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 638-644.	2.9	20
96	Meta-Analysis of Angiographic Versus Intravascular Ultrasound Parameters of Drug-Eluting Stent Efficacy (from TAXUS IV, V, and VI). <i>American Journal of Cardiology</i> , 2007, 100, 621-626.	1.6	19
97	Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 257-262.	1.7	18
98	The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention. <i>American Heart Journal</i> , 2005, 150, 1190-1197.	2.7	17
99	Pilot Candidate Gene Analysis of Patients ≥ 60 Years Old With Aortic Stenosis Involving a Tricuspid Aortic Valve. <i>American Journal of Cardiology</i> , 2012, 110, 88-92.	1.6	16
100	Effects of long-term prednisone (≥ 5 mg) use on outcomes and complications of percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2004, 93, 1389-1390.	1.6	15
101	Relation of Polymorphisms in Five Genes to Long-Term Aortocoronary Saphenous Vein Graft Patency. <i>American Journal of Cardiology</i> , 2007, 99, 1087-1089.	1.6	15
102	Length of stay and long-term mortality following ST-elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, S1-7.	1.7	15
103	Bioresorbable Stents: Is This Where We Are Headed?. <i>Progress in Cardiovascular Diseases</i> , 2015, 58, 342-355.	3.1	15
104	Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: A comparative study. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 294-300.	1.7	14
105	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. , 1997, 42, 102-108.		13
106	Genome-Wide Linkage Analysis of Large Multiple Multigenerational Families Identifies Novel Genetic Loci for Coronary Artery Disease. <i>Scientific Reports</i> , 2017, 7, 5472.	3.3	12
107	Impact of Platelet Glycoprotein IIb/IIIa Inhibition on the Paclitaxel-Eluting Stent in Patients With Stable or Unstable Angina Pectoris or Provocable Myocardial Ischemia (A TAXUS IV Substudy). <i>American Journal of Cardiology</i> , 2005, 96, 500-505.	1.6	11
108	The Weasel Clause: Excluding Patients From Door-to-Balloon Analyses. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1763.	2.8	11

#	ARTICLE	IF	CITATIONS
109	LightTyper [®] , a platform for high-throughput clinical genotyping. <i>Expert Review of Molecular Diagnostics</i> , 2005, 5, 457-471.	3.1	10
110	Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E64-E74.	1.7	10
111	Operational Efficiency and Productivity Improvement Initiatives in a Large Cardiac Catheterization Laboratory. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 329-338.	2.9	10
112	Eroding the Denominator. <i>Journal of the American College of Cardiology</i> , 2012, 60, 789-790.	2.8	9
113	Utilization and outcomes of polytetrafluoroethylene covered stents in patients with coronary artery perforation and coronary artery aneurysm: Single center 15-year experience. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 555-561.	1.7	9
114	Readmissions in ST-Elevation Myocardial Infarction and Cardiogenic Shock (from Nationwide) <i>Tj ETQq0 0 0 rgBT /Oyerlock 10,Tf 50 542</i>	1.6	9
115	A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials. <i>Current Atherosclerosis Reports</i> , 2013, 15, 341.	4.8	8
116	Genome-Wide Linkage Scan Identifies Two Novel Genetic Loci for Coronary Artery Disease: In GeneQuest Families. <i>PLoS ONE</i> , 2014, 9, e113935.	2.5	8
117	Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 116, 508-514.	1.6	8
118	Analysis of causal effect of <i>APOA5</i> variants on premature coronary artery disease. <i>Annals of Human Genetics</i> , 2018, 82, 437-447.	0.8	8
119	Long-Term Outcomes of Patients With Mediastinal Radiation-Associated Coronary Artery Disease Undergoing Coronary Revascularization With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. <i>Circulation</i> , 2020, 142, 1399-1401.	1.6	8
120	Outcomes of Early Coronary Angiography or Revascularization After Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1494-1501.	1.3	8
121	"Crying Fire in a Theater" or a "Confirmatory Sighting"? <i>Cañãž</i> Editorials published in the <i>Journal of the American College of Cardiology</i> reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2007, 50, 268-269.	2.8	7
122	Survival Prediction Models for Coronary Intervention: Strategic Decision Support. <i>Annals of Thoracic Surgery</i> , 2014, 97, 522-528.	1.3	7
123	Management of coronary chronic total occlusion. <i>Cleveland Clinic Journal of Medicine</i> , 2017, 84, 27-38.	1.3	7
124	Creation of a large-scale genetic data bank for cardiovascular association studies. <i>American Heart Journal</i> , 2005, 150, 500-506.	2.7	6
125	Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy—a propensity-adjusted analysis. <i>American Heart Journal</i> , 2006, 151, 1031.e1-1031.e6.	2.7	6
126	Implementation of a Myocardial Perfusion Imaging Risk Algorithm to Inform Appropriate Downstream Invasive Testing and Treatment. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e011984.	2.6	5

#	ARTICLE	IF	CITATIONS
127	Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. <i>American Journal of Cardiology</i> , 2002, 89, 751-753.	1.6	4
128	Angiographic predictors of adverse outcomes after percutaneous coronary intervention in patients with radiation associated coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, E104-E110.	1.7	4
129	Association of adoption of transradial access for percutaneous coronary intervention in ST elevation myocardial infarction with door-to-balloon time. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E165-E173.	1.7	4
130	Bioresorbable stents: The future of interventional cardiology?. <i>Cleveland Clinic Journal of Medicine</i> , 2016, 83, S18-S23.	1.3	4
131	The role of ISCHEMIA in stable ischemic heart disease. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 401-409.	1.3	4
132	GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention. <i>American Heart Journal</i> , 2004, 148, 1003-1006.	2.7	3
133	Frequency and factors associated with inappropriate for intervention cardiac catheterization laboratory activation. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 219-224.	0.8	3
134	Fractional flow reserve guided percutaneous coronary intervention results in reduced ischemic myocardium and improved outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 692-700.	1.7	3
135	Comparison of Long-Term Clinical Outcomes After Drug-Eluting Stenting in Blacks-vs-Whites. <i>American Journal of Cardiology</i> , 2019, 124, 1179-1185.	1.6	3
136	Restenosis, Statistics, and Reasonable Inferences. <i>Journal of the American College of Cardiology</i> , 2006, 47, 470-471.	2.8	2
137	Percutaneous Left Main Intervention. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 642-647.	2.9	2
138	Fantom Bioresorbable Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1839-1840.	2.9	2
139	Coronary Tortuosity and Long-Term Post-Stent Risk. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1019-1020.	2.9	2
140	Intravascular ultrasound predictors of long-term outcomes following ABSORB bioresorbable scaffold implantation: A pooled analysis of the ABSORB III and ABSORB Japan trials. <i>Journal of Cardiology</i> , 2021, 78, 224-229.	1.9	2
141	Abstract 17910: Patients with Newly Diagnosed Diabetes Have Comparable Long Term Mortality with Known Diabetics After ST Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2014, 130, .	1.6	2
142	First human randomized trial of G-CSF stem cell mobilization to treat large acute myocardial infarction—preliminary results of a pilot study. <i>International Congress Series</i> , 2004, 1262, 364-367.	0.2	1
143	Stent choice and the hidden consequences of cost savings. <i>Nature Reviews Cardiology</i> , 2012, 9, 559-560.	13.7	1
144	Do We Know the Best Treatment for In-Stent Restenosis Via Network Meta-Analysis (NMA)?. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 395-397.	2.9	1

#	ARTICLE	IF	CITATIONS
145	CLINICAL, ANGIOGRAPHIC AND PROCEDURAL CORRELATES OF ABSORB SCAFFOLD THROMBOSIS: A MATCHED MULTICENTER REGISTRY ANALYSIS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 964.	2.8	1
146	Walking the right path: the story of bioresorbable stents. <i>Journal of Thoracic Disease</i> , 2017, 9, 1786-1788.	1.4	1
147	CTO Coronary Perforations. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1913-1914.	2.9	1
148	How Should We Treat Patients With Silent Myocardial Ischemia?. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 242-244.	2.9	1
149	End-stage renal disease as an independent risk factor for in-hospital mortality after coronary drug-eluting stenting: Understanding and modeling the risk. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 246-254.	1.7	1
150	Successful modeling of long term outcomes in end-stage renal disease patients undergoing percutaneous coronary intervention with drug-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 208-214.	1.7	1
151	Incidence, treatment, and outcomes of acute myocardial infarction following transcatheter or surgical aortic valve replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	1.7	1
152	Quantitative evaluation of local drug delivery using the InfusaSleeve catheter. <i>Catheterization and Cardiovascular Diagnosis</i> , 1997, 42, 102-108.	0.3	1
153	Unprotected Left Main Coronary Artery Disease: Management in the Post NOBLE and EXCEL Era. <i>Interventional Cardiology Review</i> , 2017, 12, 92.	1.6	1
154	Abstract 16161: Bone Marrow Characteristics are Associated With Changes in Infarct Size Following STEMI: A Biorepository Evaluation From the CCTRN TIME Trial. <i>Circulation</i> , 2014, 130, .	1.6	1
155	Outcomes of Interventional Management of Coronary Artery Disease in Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2022, 54, 663-663.	0.6	1
156	Presence of Diabetes Does Not Matter for Percutaneous Coronary Intervention Outcomes With Simple Coronary Lesions. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2119-2120.	2.8	0
157	Role of Revascularization to Improve Left Ventricular Function. <i>Heart Failure Clinics</i> , 2015, 11, 203-214.	2.1	0
158	Bioresorbable Vascular Scaffolds. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 796-797.	2.9	0
159	Assessing the Likelihood of Chronic Total Occlusion Percutaneous Coronary Intervention Procedural Success. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 343-345.	2.9	0
160	Prediabetic Patient Outcomes 8 to 15 Years After Drug-Eluting Coronary Stenting. <i>American Journal of Cardiology</i> , 2021, 149, 21-26.	1.6	0
161	Abstract 17075: Outcomes in Radiation Associated Cardiac Disease Patients that present with Coronary Artery Disease: Comparison between PCI and CABG. <i>Circulation</i> , 2014, 130, .	1.6	0
162	Abstract 10954: Clinical and Angiographic Predictors of Adverse Outcomes After Percutaneous Coronary Intervention in Patients With Radiation Associated Coronary Artery Disease. <i>Circulation</i> , 2015, 132, .	1.6	0

#	ARTICLE	IF	CITATIONS
163	Abstract 14566: Mild Elevation in Cardiac Troponin T is Independently Associated With Long-Term Mortality After Intermediate or High-Risk Vascular Surgery. <i>Circulation</i> , 2015, 132, .	1.6	0
164	Feasibility of transradial primary percutaneous coronary intervention for <scp>STEMI</scp> complicated by cardiac arrest. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1363-1365.	1.7	0
165	Incremental progress? The roles of direct stenting and routine troponin measurement after percutaneous coronary intervention. <i>Journal of Invasive Cardiology</i> , 2002, 14, 171-2.	0.4	0
166	Plaque that makes a patient vulnerable. <i>Journal of Invasive Cardiology</i> , 2004, 16, 401.	0.4	0